NUMINUS WELLNESS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.05 CAD | 0.00% |
|
0.00% | -54.55% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.91M 15.96M 1.26B | Sales 2025 * | 33.35M 24.3M 1.91B | Capitalization | 16.03M 11.68M 919M |
|---|---|---|---|---|---|
| Net income 2024 * | -16M -11.66M -918M | Net income 2025 * | -3M -2.19M -172M | EV / Sales 2024 * | 0.73 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.48 x |
| P/E ratio 2024 * |
-0.83
x | P/E ratio 2025 * |
-5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Numinus Wellness Inc.
More press releases
More news
| Current month | -23.08% | ||
| 1 month | -28.57% | ||
| 3 months | -47.37% | ||
| 6 months | -58.33% | ||
| Current year | -54.55% |
1 week
0.05
0.06
1 month
0.040.08
Current year
0.040.20
1 year
0.040.27
3 years
0.041.18
5 years
0.042.45
10 years
0.042.45
| Managers | Title | Age | Since |
|---|---|---|---|
Payton Nyquvest
CEO | Chief Executive Officer | - | 26/06/62 |
Michael Tan
PSD | President | - | 31/12/18 |
Paul Thielking
CTO | Chief Tech/Sci/R&D Officer | - | 09/06/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Larry Timlick
BRD | Director/Board Member | 67 | 27/01/19 |
Allen Morishita
BRD | Director/Board Member | 75 | 08/03/12 |
Payton Nyquvest
CEO | Chief Executive Officer | - | 26/06/62 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/24 | 0.05 | 0.00% | 256 279 |
| 18/06/24 | 0.05 | 0.00% | 271,701 |
| 17/06/24 | 0.05 | 0.00% | 146,730 |
| 14/06/24 | 0.05 | 0.00% | 424,751 |
| 13/06/24 | 0.05 | 0.00% | 771,277 |
Delayed Quote Toronto S.E., June 19, 2024 at 06:53 pm
More quotes
Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.
Calendar
01/07/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.05
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -54.55% | 11.68M | |
| +34.01% | 51.07B | |
| +33.84% | 38.86B | |
| -8.02% | 38.78B | |
| -8.98% | 26.69B | |
| +12.56% | 26.35B | |
| -19.62% | 19.46B | |
| +39.18% | 13.58B | |
| +31.47% | 12.46B | |
| -3.40% | 11.75B |
- Stock Market
- Equities
- NUMI Stock
